Pharmaceutical formulations of TNF-alpha antibodies
The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations. Additionally, the novel formulations of the present invention prevents the formation of aggregates or fragments or modifications of protein in solution.
1. A liquid pharmaceutical composition comprising:
(a) an effective amount of adalimumab or an antigen binding portion thereof;
(b) a stabilizer consisting essentially of:
(i) from about 0.5% to about 10% arginine, or
(ii) from about 0.5% to about 10% arginine and from about 1% to about 10% sorbitol;
(c) 0.01% to 1% of a surfactant selected from polysorbate 80, polysorbate 20 or a combination thereof; and
(d) 5-50 mM succinate buffer, pH 5.0 to 5.5.
2. The composition of claim 1 , wherein the stabilizer consists essentially of 0.5% to about 10% arginine.
3. The composition of claim 1 , wherein the stabilizer consists essentially of 5 mg/mL arginine.
4. The composition of claim 1 , wherein the stabilizer consists essentially of 0.5% to about 10% arginine and from about 1% to about 10% sorbitol.
5. The composition of claim 1 , wherein the stabilizer consists essentially of 5 mg/mL arginine and 10 mg/mL sorbitol.
6. The composition of claim 1 , wherein the surfactant is polysorbate 80.
7. The composition of claim 6 , wherein the surfactant comprises 0.1 mg/mL polysorbate 80.
8. The composition of claim 1 , wherein the composition comprises 10 mM succinate buffer.
9. The composition of claim 1 , further comprising a tonicity agent.
10. The composition of claim 9 , wherein the tonicity agent comprises sodium chloride.
11. The composition of claim 10 , wherein tonicity agent comprises from about 10 mM to about 150 mM sodium chloride.